AutoZone Authorizes Additional Stock Repurchase
MEMPHIS, Tenn., Dec. 20, 2023 (GLOBE NEWSWIRE) — AutoZone, Inc. (NYSE: AZO), today announced its Board of Directors authorized the […]
Rogers Communications 4Q23 Investment Community Teleconference February 1, 2024 at 8:00 a.m. ET
TORONTO, Dec. 20, 2023 (GLOBE NEWSWIRE) — Rogers Communications Inc. (TSX: RCI.A and RCI.B) (NYSE: RCI) plans to release its […]
TSX News -
European Residential Real Estate Investment Trust Announces Conclusion of Strategic Review Process
TORONTO, Dec. 20, 2023 (GLOBE NEWSWIRE) — European Residential Real Estate Investment Trust (“ERES” or the “REIT”) (TSX: ERE.UN) announced […]
Galantas Gold Announces Closing of US$2.6 Million Private Placement of Unsecured Convertible Debentures and Terms of Debt Settlement Transaction
Not for distribution to United States news wire services or for dissemination in the United States TORONTO, Dec. 20, 2023 […]
U.S. Federal Circuit Affirms Earlier PTAB Decision to Invalidate All Claims of United Therapeutics Patent No. 10,716,793 (‘793 Patent)
Liquidia will pursue final FDA approval for YUTREPIA™ (treprostinil) inhalation Liquidia will immediately request that District Court set aside injunction […]
Park Hotels & Resorts Update on Recent Operating Trends and Capital Allocation Highlights
TYSONS, Va., Dec. 20, 2023 (GLOBE NEWSWIRE) — Park Hotels & Resorts Inc. (“Park” or the “Company”) (NYSE:PK) today provided […]
Mawson Infrastructure Group Inc. Announces Monthly Operational Update for November 2023
November Total Revenue increased 47% M/M November Total Revenue of Bitcoin Equivalent of 132 BTC1 Completed Co-Location Customer Deployment of […]
CVB Financial Corp. Announces 137th Consecutive Quarterly Cash Dividend
ONTARIO, CA, Dec. 20, 2023 (GLOBE NEWSWIRE) — CVB Financial Corp. (NASDAQ: CVBF) (the “Company”) announced a twenty cent ($0.20) […]
Roivant Reports Positive Initial Phase 2 Results for Batoclimab in Graves’ Disease
NEW YORK, Dec. 20, 2023 (GLOBE NEWSWIRE) — Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal […]
Immunovant Reports Positive Initial Phase 2 Results for Batoclimab in Graves’ Disease
NEW YORK, Dec. 20, 2023 (GLOBE NEWSWIRE) — Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal […]
